BRASKM; Ba3/BBneg/BB
We view the results from Braskem as very weak and credit negative and wouldn’t be surprised with rating actions following these results.
Gross revenues were -5% vs Q125 at $3.15bn and recurring EBITDA was significantly lower -66% vs Q125 at $74mn. Geographically all regions contributed to a weak quarter, with no region showing any resilience to the weaker pricing backdrop: Geographically:
- US and EU: Top line was -10% QoQ, while margins remain very thin, with gross margin of only 1% resulting in EBITDA loss of -$8mn vs $20mn profit in Q125.
- Brazil/ South America: Utilisation stable at 74%, revenues were -1% vs Q125 while recurring EBITDA was -24% vs Q1 25 at $152mn.
- Mexico Utilisation down to 44% in Q2 25 down from 79% in Q1 25, volumes were 16% vs Q125 and recurring EBITDA was -$9mn vs $31mn in Q125.
Find more articles and bullets on these widgets:
SFIZ5 96.15p x2 vs 96.50c x1, sold the Call at -2.75 in 4k.
As a side note, more interestingly there's a HUGE 472.4k worth of OI in the 20p, of the same expiry.